Who are COS with GnRH antagonists and HP-HMG's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cos-with-gnrh-antagonists-and-hp-hmg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

COS with GnRH antagonists and HP-HMG — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COS with GnRH antagonists and HP-HMG (COS with GnRH antagonists and HP-HMG) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin protocol / Assisted reproductive technology regimen. Area: Reproductive Medicine / Infertility.

marketed Gonadotropin protocol / Assisted reproductive technology regimen GnRH receptor (antagonism); FSH receptor and LH receptor (agonism via exogenous gonadotropins) Reproductive Medicine / Infertility Small molecule Live · refreshed every 30 min

Target snapshot

COS with GnRH antagonists and HP-HMG (COS with GnRH antagonists and HP-HMG) — Instituto Valenciano de Infertilidad, IVI VALENCIA. This protocol combines controlled ovarian stimulation (COS) with GnRH antagonists to suppress premature luteinizing hormone surge and HP-HMG (highly purified human menopausal gonadotropin) to stimulate multiple follicle development for assisted reproductive technology.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
COS with GnRH antagonists and HP-HMG TARGET	COS with GnRH antagonists and HP-HMG	Instituto Valenciano de Infertilidad, IVI VALENCIA	marketed	Gonadotropin protocol / Assisted reproductive technology regimen	GnRH receptor (antagonism); FSH receptor and LH receptor (agonism via exogenous gonadotropins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gonadotropin protocol / Assisted reproductive technology regimen class)

Instituto Valenciano de Infertilidad, IVI VALENCIA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). COS with GnRH antagonists and HP-HMG — Competitive Intelligence Brief. https://druglandscape.com/ci/cos-with-gnrh-antagonists-and-hp-hmg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab